Sugi Predict

Sugi Predict / Compounds / SCHEMBL3035704

SCHEMBL3035704

SCHEMBL3035704

O=C(NCCNCc1ccc(Oc2ccccc2)cc1)c1ccc(-c2nn[nH]n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ XDH P47989 3/20 0.61
▸ EPHX2 P34913 2/20 0.56
▸ NR1H4 Q96RI1 1/20 0.56
▸ HPGD P15428 1/20 0.51
▸ MAPK14 Q16539 3/20 0.51
▸ LMNA P02545 2/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ MMP13 P45452 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ LTA4H P09960 1/20 0.50
▸ ERCC5 P28715 1/20 0.49
▸ FEN1 P39748 1/20 0.49
▸ CA12 O43570 1/20 0.49
▸ CA1 P00915 1/20 0.49
▸ CA2 P00918 1/20 0.49
▸ MMP2 P08253 1/20 0.49
▸ CA9 Q16790 1/20 0.49
▸ CYSLTR1 Q9Y271 1/20 0.49
▸ HDAC3 O15379 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3043353 0.89 FAAH (0.51) XDHEPHX2NR1H4HPGDMAPK14
SCHEMBL3039097 0.87 FAAH (0.60) XDHEPHX2NR1H4LMNALTA4H
SCHEMBL3035510 0.86 FAAH (0.61) XDHEPHX2NR1H4LMNALTA4H
SCHEMBL4755507 0.83 HPGD (0.64) EPHX2HPGDMAPK14LMNACYP3A4
SCHEMBL3038826 0.82 HPGD (0.63) EPHX2NR1H4HPGDMAPK14LMNA
SCHEMBL3039071 0.80 EPHX2 (0.64) EPHX2HPGDMAPK14LMNACYP3A4
SCHEMBL1250866 0.79 XDH (0.74) XDHNR1H4LTA4HERCC5FEN1
SCHEMBL1249320 0.79 LTA4H (0.55) XDHLTA4HERCC5FEN1
SCHEMBL3035490 0.77 HPGD (0.56) EPHX2HPGDMAPK14LMNACYP3A4
SCHEMBL3041481 0.74 MAPK14 (0.53) EPHX2HPGDMAPK14LMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296935-A1 Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase CELLTAXIS LLC (US) 2025-09-25 — — US disclosed
US-12173009-B2 Diamine derivatives as inhibitors of leukotriene A4 hydrolase CELLTAXIS, LLC (US) 2024-12-24 — — US disclosed
US-20230250104-A1 DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE CELLTAXIS LLC (US) 2023-08-10 — — US disclosed
US-11267819-B2 Diamine derivatives as inhibitors of leukotriene A4 hydrolase Celltaxsis, LLC (US) 2022-03-08 — — US disclosed
US-20200308181-A1 DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE CELLTAXIS, LLC 2020-10-01 — — US disclosed
EP-3205644-A1 DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE Celtaxsys Inc. (US) 2017-08-16 — — EP disclosed
EP-1976828-B1 DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE CELTAXSYS INC (US) 2016-12-21 — — EP disclosed
US-20160272649-A1 DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE CELTAXSYS INC (US) 2016-09-22 — — US disclosed
US-9315509-B2 Diamine derivatives as inhibitors of leukotriene A4 hydrolase CELTAXSYS, INC. (US) 2016-04-19 — — US disclosed
US-20150080382-A1 DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE DOMAIN PARTNERS VIII, L.P. 2015-03-19 — — US disclosed
US-8569303-B2 Diamine derivatives as inhibitors of leukotriene A4 hydrolase CELTAXSYS, INC. (US) 2013-10-29 — — US disclosed
US-20130123243-A1 DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE CELTAXSYS, INC. 2013-05-16 — — US disclosed
US-20100210630-A1 Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase ESTRELLITA PHARMACEUTICALS, LLC 2010-08-19 — — US disclosed
US-7737145-B2 Diamine derivatives as inhibitors of leukotriene A4 hydrolase ESTRELLITA PHARMACEUTICALS, LLC (US) 2010-06-15 — — US disclosed
US-20070155726-A1 Diamine derivatives as inhibitors of leukotriene A4 hydrolase SCHERING AKTIENGESELLSCHAFT (DE) 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123243-A1 DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE LTA4H, LTB4R, LTC4S XDH 1167/4885EPHX2 103/4885NR1H4 205/4885
US-12173009-B2 Diamine derivatives as inhibitors of leukotriene A4 hydrolase LTA4H, LTB4R, LTC4S XDH 1167/4885EPHX2 103/4885NR1H4 205/4885
US-20150080382-A1 DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE LTA4H, LTB4R, LTC4S XDH 1167/4885EPHX2 103/4885NR1H4 205/4885
US-20250296935-A1 Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase LTA4H, LTB4R, LTC4S XDH 1167/4885EPHX2 103/4885NR1H4 205/4885
US-20070155726-A1 Diamine derivatives as inhibitors of leukotriene A4 hydrolase LTA4H, LTB4R, LTC4S XDH 1167/4885EPHX2 103/4885NR1H4 205/4885
US-11267819-B2 Diamine derivatives as inhibitors of leukotriene A4 hydrolase LTA4H, LTB4R, LTC4S XDH 1167/4885EPHX2 103/4885NR1H4 205/4885
US-20230250104-A1 DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE LTA4H, LTB4R, LTC4S XDH 1167/4885EPHX2 103/4885NR1H4 205/4885
US-20200308181-A1 DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE LTA4H, LTB4R, LTC4S XDH 1167/4885EPHX2 103/4885NR1H4 205/4885
US-20100210630-A1 Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase LTA4H, LTB4R, LTC4S XDH 1167/4885EPHX2 103/4885NR1H4 205/4885
US-20160272649-A1 DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE LTA4H, LTB4R, LTC4S XDH 1167/4885EPHX2 103/4885NR1H4 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.